A recent study has shown that patients with relapsed or refractory chronic lymphocytic leukemia may prolong their progression-free survival after treatment with a specific combination regimen.
An adjuvant combination regimen may improve the rate of relapse-free survival by 19% in patients with stage III BRAF-mutated melanoma.
Patients with hepatocellular carcinoma who took a reduced therapy dose had a lower cumulative pill cost and were less likely to discontinue treatment due to toxicities.
Following a recent literature review, a team of researchers have proposed new guidelines for the systematic management of side effects associated with CAR-T cell treatment.
A recent study examined whether inpatient palliative care during hematopoietic stem-cell transplant leads to long-term improvements in quality of life and symptom burden for patients.
Previously-treated patients with stage IV NSCLC are less likely to utilize palliative care or hospice services compared with those who receive no prior oncologic treatment.
A patient-driven titration regimen demonstrated better HbA1C control without increasing the risk of hypoglycemia than a physician-driven titration regimen in patients with type 2 diabetes.
The US Food and Drug Administration approved a lower dose of a previously approved therapy for prostate cancer after reviewing a post-marketing study.
The National Comprehensive Cancer Network has released their latest guidelines for the treatment of pancreatic adenocarcinoma, featuring a new therapy in the second-line setting.
Researchers have developed a novel prognostic assay that identifies patients with Hodgkin lymphoma with unfavorable post-ASCT outcomes after relapse.